Source: Kapitales Research

Highlights:

• Pro Medicus Limited landed a seven-year agreement valued at AU$90 million with Beth Israel Lahey Health.
• The agreement includes the company’s full Visage 7 imaging platform delivered through the cloud
• The deal reinforces growing demand for cloud-based healthcare imaging solutions across North America

Pro Medicus Limited (ASX: PME) has strengthened its position in the global healthcare imaging sector after securing a major long-term contract with US-based healthcare provider Beth Israel Lahey Health. The ASX-listed medical imaging technology company announced that its wholly owned US subsidiary, Visage Imaging, signed a seven-year agreement valued at approximately AU$90 million. Pro Medicus will provide its Visage 7 cloud imaging solution across the broader Beth Israel Lahey Health system as part of the long-term agreement.

Demand Rises for Enterprise Imaging Platforms

The partnership incorporates Pro Medicus’ entire Visage 7 product suite, covering viewing, workflow and archive functions. The platform will support enterprise-wide diagnostic imaging while also integrating with Beth Israel Lahey Health’s electronic health record systems. The healthcare network operates 14 hospitals across Eastern Massachusetts and Southern New Hampshire, alongside thousands of physicians and healthcare staff. Pro Medicus stated that planning for the rollout is set to begin immediately, with the platform expected to go live during the first quarter of 2027.

The transaction is based on a usage-driven licensing model, which could provide additional upside beyond the initial contract value depending on platform utilisation levels.

North American Momentum Continues

The latest contract further highlights Pro Medicus’ growing footprint in the North American healthcare IT market, particularly as hospitals continue shifting toward scalable cloud-based imaging infrastructure.

Chief Executive Officer Sam Hupert said the agreement reflected increasing industry adoption of the company’s cloud-focused strategy. The company also noted that demand for its broader “full stack” offering — combining imaging viewer, workflow and archive capabilities — continues to strengthen across healthcare systems.

Why the Deal Matters

The contract reinforces Pro Medicus’ reputation as one of Australia’s leading healthcare technology companies and signals continued investment in digital healthcare infrastructure globally. As healthcare providers increasingly prioritise efficiency, scalability and faster imaging access, cloud-based enterprise imaging platforms are becoming a larger part of long-term hospital technology strategies.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au